Breaking News Instant updates and real-time market news.

NHYDY

Norsk Hydro

$0.00

(0.00%)

, CENX

Century Aluminum

$9.96

-0.27 (-2.64%)

19:44
10/07/18
10/07
19:44
10/07/18
19:44

Hydro says Alunorte receives authorization to utilize press filter

Norsk Hydro (NHYDY) announced over the weekend that its alumina refinery Alunorte was granted an exceptional authorization, on October, 5, by federal environmental agency IBAMA to utilize its press filter technology in its processing of bauxite residues, which will extend the life of its DRS1 bauxite residue disposal area and allow Alunorte to continue operations on safe conditions. Following IBAMA's decision, Alunorte will be working with SEMAS, Secretary of State for Environment and Sustainability, to obtain the authorization to use the press filter on DRS1, the company said. This filter provides stackable residues with less water content than the drum filter, it added. After receiving this authorization, Alunorte will be able to re-start the operation at 50% of capacity. "We are ready to re-start our operations and we thank for all the support that we have received from the authorities and society. We are now making every effort to go back to producing as we maintain our dialog with authorities to resume full production," said John Thuestad, head of Hydro's Bauxite and Alumina business area. Thuestad adds that resuming 50% production at Alunorte would also allow Hydro's bauxite mine Paragominas and its joint-venture primary aluminium smelter Albras to continue operating at half capacity, as opposed to being fully shut down as a consequence of Alunorte being idled. Following news last week that Hydro was preparing for full curtailment of Alunorte operations, shares of Century Aluminum (CENX) fell while Alcoa (AA) rose. Reference Link

NHYDY

Norsk Hydro

$0.00

(0.00%)

CENX

Century Aluminum

$9.96

-0.27 (-2.64%)

AA

Alcoa

$42.08

-1.025 (-2.38%)

  • 17

    Oct

NHYDY Norsk Hydro
$0.00

(0.00%)

09/10/18
JPMS
09/10/18
UPGRADE
JPMS
Overweight
Norsk Hydro upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Dominic O'Kane upgraded Norsk Hydro to Overweight with a price target of 54 kroner.
10/03/18
JPMS
10/03/18
DOWNGRADE
JPMS
Neutral
Norsk Hydro downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Dominic O'Kan downgraded Norsk Hydro to Neutral after the company announced the full curtailment of Alunorte. The "goal posts have been moved," O'Kan says in a research note.
10/07/18
GSCO
10/07/18
UPGRADE
GSCO
Buy
Norsk Hydro upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Norsk Hydro to Buy after Alunorte resolution.
09/25/18
MSCO
09/25/18
UPGRADE
MSCO
Overweight
Norsk Hydro upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Menno Sanderse upgraded Norsk Hydro to Overweight with a price target of 59 kroner. The analyst views the recent pullback in the Europe metals and mining sector as a buying opportunity.
CENX Century Aluminum
$9.96

-0.27 (-2.64%)

10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Deutsche downgrades Century Aluminum on growing risks, reduced upside
Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20. Century's margins could remain pressured for longer due to alumina supply disruptions, Kliewer tells investors in a research note. Further, the analyst feels little progress has been made with Santee Cooper, the electrical supplier at the company's Mt. Holly smelter, and that support for import tariffs may decline further following the November mid-term elections. As such, the analyst sees reduced upside potential and growing risk for Century Aluminum shares.
10/02/18
10/02/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GE UPGRADED AT RBC, WOLFE: RBC Capital analyst Deane Dray upgraded General Electric (GE) to Outperform from Sector Perform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO. Additionally, GE was upgraded to Outperform from Peer Perform at Wolfe Research. DEUTSCHE SEES HEIGHTENED RISKS TO FACEBOOK ESTIMATES: After attending the first day of AdWeek, Deutsche Bank analyst Lloyd Walmsley sees heightened risk to the Q3, Q4 and 2019 consensus estimates for Facebook (FB). The analyst said he's starting to hear more cautious feedback and that Facebook seems on the defensive, particularly following last week's data breach disclosure. Walmsley, however, continues to view Facebook as attractively valued and kept a Buy rating on the shares with a $205 price target. JPMORGAN ADDS WEIGHT WATCHERS TO FOCUS LIST: JPMorgan analyst Christina Brathwaite added Weight Watchers (WTW) to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite said. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward. AMBEV DOUBLE DOWNGRADED BY UBS: UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis believes. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds. DEUTSCHE DOWNGRADES METAL STOCKS: Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20, stating that Century's margins could remain pressured for longer due to alumina supply disruptions. Meanwhile, Deutsche's Chris Terry downgraded Reliance Steel (RS) to Hold from Buy and lowered his price target for the shares to $90 from $100, and downgraded U.S. Steel (X) to Hold from Buy and lowered his price target for the shares to $35 from $47. The analyst said his view on the steel sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry believes.
10/04/18
RILY
10/04/18
NO CHANGE
Target $20
RILY
Buy
Century Aluminum price target lowered to $20 from $23 at B. Riley FBR
B. Riley FBR analyst Lucas Pipes lowered his price target for Century Aluminum to $20 after adjusting his estimates for the company and Aloca (AA) to reflect expected Q3 price realizations and his firm's upgraded long-term price deck. The analyst keeps a Buy rating on the shares.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Century Aluminum downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Century Aluminum to Hold and lowered his price target for the shares to $15 from $20. The analyst sees growing risks and reduced upside potential at current share levels.
AA Alcoa
$42.08

-1.025 (-2.38%)

09/21/18
BREN
09/21/18
INITIATION
Target $54
BREN
Buy
Alcoa initiated with a Buy at Berenberg
Berenberg analyst Paretosh Misra initiated Alcoa with a Buy and $54 price target due to improved aluminum market fundamentals and outlook and sees upside into the winter supply curtailment in China.
09/25/18
FBCO
09/25/18
NO CHANGE
Target $58
FBCO
Outperform
Alcoa price target lowered to $58 from $65 at Credit Suisse
Credit Suisse analyst Curt Woodworth lowered his price target for Alcoa to $58 from $65 as he believes the company's Q3 results will be negatively impacted by dynamics with higher profitability in the alumina segment and some cost creep in the smelter portfolio. The analyst reiterates an Outperform rating on the shares.
09/12/18
RILY
09/12/18
UPGRADE
Target $50
RILY
Buy
B. Riley FBR upgrades Alcoa to Buy on elevated alumina prices
B. Riley FBR analyst Lucas Pipes earlier today upgraded Alcoa (AA) to Buy from Neutral and raised his price target for the shares to $50 from $48. The analyst says Alumina prices have exceeded his expectations and that the "current elevated price benefits Alcoa disproportionately." Further, with a Rusal sanction resolution unlikely and Alunorte not expected at full capacity until mid-2019, the trends for alumina are bullish, Pipes tells investors in a research note. He keeps a Buy rating on Century Aluminum (CENX) while lowering his price target for the shares to $23 from $25. Alcoa in early trading is up 10c to $40.97.
09/12/18
RILY
09/12/18
UPGRADE
Target $50
RILY
Buy
Alcoa upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Lucas Pipes upgraded Alcoa to Buy and raised his price target for the shares to $50 from $48.

TODAY'S FREE FLY STORIES

V

Visa

$140.06

0.74 (0.53%)

, IBM

IBM

$129.16

-1.36 (-1.04%)

17:45
10/21/18
10/21
17:45
10/21/18
17:45
Hot Stocks
Visa readies B2B Connect for market »

Visa (V) announced new…

V

Visa

$140.06

0.74 (0.53%)

IBM

IBM

$129.16

-1.36 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 28

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

  • 03

    Mar

T

AT&T

$32.86

0.36 (1.11%)

, CMCSA

Comcast

$35.97

0.02 (0.06%)

17:42
10/21/18
10/21
17:42
10/21/18
17:42
Hot Stocks
Box Office Battle: 'Halloween' breaks records with scary $77.5M »

Comcast (CMCSA)…

T

AT&T

$32.86

0.36 (1.11%)

CMCSA

Comcast

$35.97

0.02 (0.06%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.66

-0.38 (-0.68%)

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

LGF.A

Lionsgate

$22.20

(0.00%)

DIS

Disney

$118.81

2.55 (2.19%)

VIAB

Viacom

$33.24

-0.49 (-1.45%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOX

21st Century Fox

$45.51

0.05 (0.11%)

, FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

17:24
10/21/18
10/21
17:24
10/21/18
17:24
Periodicals
AMC's Collier named next leader of Fox Network, NY Times reports »

Fox (FOXA) will turn to…

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

17:04
10/21/18
10/21
17:04
10/21/18
17:04
Periodicals
Audi electric SUV facing delay due to software bug, Reuters reports »

Audi's first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$34.66

-0.61 (-1.73%)

17:00
10/21/18
10/21
17:00
10/21/18
17:00
Periodicals
Blackstone to acquire Ulterra for $700M, Reuters reports »

Blackstone has agreed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

, KKR

KKR

$24.22

-0.45 (-1.82%)

16:56
10/21/18
10/21
16:56
10/21/18
16:56
Periodicals
Fiat agrees to sell Magneti Marelli to KKR's Calsonic, Bloomberg says »

Fiat Chrysler (FCAU) has…

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

KKR

KKR

$24.22

-0.45 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 30

    Oct

MRK

Merck

$72.34

0.12 (0.17%)

, AZN

AstraZeneca

$39.21

0.25 (0.64%)

16:40
10/21/18
10/21
16:40
10/21/18
16:40
Hot Stocks
Merck, AstraZeneca announce detailed results from Phase 3 SOLO-1 trial »

AstraZeneca (AZN) and…

MRK

Merck

$72.34

0.12 (0.17%)

AZN

AstraZeneca

$39.21

0.25 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.